BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
| 适应症 | Atopic Dermatitis, Skin Diseases, Eczema |
|---|---|
| 分期 | 不适用 |
| 申办方 | Women's College Hospital |
| 状态 | 提前终止 |
| 受试者人数 | 69 人 |
| 干预（药物） | Narrowband UVB phototherapy, Broadband UVB phototherapy |
| 开始日期 | 2021年9月27日 |
| 完成日期 | 2025年6月5日 |
| 结果公布日 | 2026年7月21日 |
摘要
Atopic dermatitis (eczema) is a complicated skin condition. In fact, it represents many different underlying problems. These include abnormalities in the skin barrier, the immune system and the ability to handle different bacteria. Despite many recent gains in the understanding of eczema, a lot needs to be learned. There is little evidence to select between some of the older treatments that are available now. Even the newest targeted therapy does not clear most patients' skin. In order to improve the understanding of eczema, how to treat it now, and to enable discovery of new treatments, the investigators plan to enroll patients into a large study at three centres in Canada (University of Toronto, McGill University and University of British Columbia). The study is called the Canadian Atopic Dermatitis Cohort for Translational Immunology and Imaging (CACTI). In this study, the investigators will collect data on how severe participants' eczema is and what treatments they use. For participants who give permission, the investigators will collect blood and skin biopsy samples to study the mechanisms underlying their disease. The investigators will test to see which form of phototherapy
Absolute Change From Baseline (95% CrI) in the Eczema Area and Severity Index (EASI)
| Narrowband UVB | -8.9 units on a scale |
|---|---|
| Broadband UVB | -8.1 units on a scale |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen